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about it,ibi
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The  use  and  abuse  of  antibiotics  may  be  considered  an
overly  prevalent  theme  of  discussion  in  a  country  such  as
Mexico,  but  unfortunately  it  is  a  practice  that,  despite
past  efforts,  continues  to  have  harmful  and  irreversible
consequences.  On  May  27,  2010,  the  Diario  Oﬁcial  de  la  Fed-
eración  published  a  law  stating  that  ‘‘antibiotics  can  only  be
administered  when  prescribed  by  legally  authorized  health
professionals  in  order  to  control  their  use  and  abuse,  limiting
the  negative  consequences  of  inadequate  prescription  and
contributing  to  preserving  the  health  of  the  Mexican  popula-
tion’’.1 Two  of  the  many  important  reasons  for  passing  this
law  are:
1.  The  increasing  bacterial  resistance  in  pathogens  causing
community-acquired  and  hospital-acquired  infections  in
Mexico
2.  To  prevent  self-medication  and  the  creation  of  bacterial
strains  that  are  resistant  to  medication  effectiveness
The  indiscriminate  and  unjustiﬁed  use  of  antibiotics  has
various  consequences,  but  perhaps  the  most  serious  is  resis-
tance,  which  happens  to  be  much  higher  in  the  developing
countries.2 How  alarming  is  this  situation  for  Mexico?  Conclu-
sions  drawn  from  the  following  examples  can  help  answer
that  question:2
1.  The  resistance  of  S.  pneumoniae  to  penicillin  is  70%.
2.  The  resistance  of  Shigella  spp  to  ampicillin  and  co-
trimoxazole  is  81%.
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.  More  than  40%  of  the  strains  of  Pseudomona  are  resistant
to  imipenem,  ceftazidime,  and  levoﬂoxacin.
In  the  current  issue  of  our  Journal,  Novoa-Farías  et  al.3
resent  an  exceptional  study  on  the  susceptibility  of
nteropathogen  bacteria  isolated  in  Mexican  patients  with
cute  gastroenteritis  to  rifaximin  and  other  antimicrobials.
he  present  work  stresses  the  fact  that  oral  rehydration
herapy  is  the  standard  treatment  for  acute  gastroenteri-
is  (as  recommended  in  the  Mexican  Gastroenterological
ssociation’s  ‘‘Guidelines  for  the  Diagnosis  and  Treatment
f  Diarrhea’’4)  and  that  antimicrobial  agents  are  recom-
ended  only  in  severe  or  prolonged  cases.  In  this  context,
here  are  2  relevant  aspects  to  understanding  the  sus-
eptibility  to  antimicrobials  of  the  gastroenteritis-causing
acteria:  the  attempt  to  initiate  early  therapeutic  man-
gement  and  the  epidemiologic  surveillance  of  bacterial
esistance.  As  shown  by  the  authors  through  the  analysis
f  bacterial  sensitivity  and  stool  samples  obtained  from
,000  subjects  in  Mexico  City  with  acute  enteral  infec-
ion,  the  susceptibility  of  the  enteropathogenic  bacteria
E.  coli,  Shigella,  Salmonella, etc.)  to  antibiotics  formerly
onsidered  ﬁrst-line  is  lower  than  70%:  ciproﬂoxacin  67.3%,
urazolidone  64.7%,  trimethoprim-sulfamethoxazole  54.1%,
nd  ampicillin  32.2%.  In  other  words,  today’s  patient  with
nteral  symptoms  receiving  sulfas  has  a  50%  probability  of
neffective  treatment.
Antibiotic  resistance  has  recently  been  described  as  a
ituation  related  to  genetic  factors.  For  example,  it  has
een  suggested  that  drugs  that  are  frequently  used  in  Latin
merica,  such  as  quinolones  or  tetracyclines,  promote  genes
ssociated  with  antimicrobial  resistance.5,6 The  observation
n  the  study  by  Novoa-Farías  et  al.  that  close  to  50%  of
he  enteropathogen  or  enterotoxigenic  E.  coli  strains  are
esistant  to  ciproﬂoxacin  supports  this  concept.Despite  the  discouraging  epidemiologic  results,  the
uthors  show  that  rifaximin  at  the  recommended  doses
s  efﬁcacious  against  99-100%  of  the  bacteria  identiﬁed
s  causing  acute  bacterial  gastroenteritis  in  Mexico.
 by Masson Doyma México S.A. This is an open access article under
d/4.0/).
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ifaximin,  an  analog  of  rifamycin,  is  a  semi-synthetic
ntibiotic  designed  to  have  little  gastrointestinal  absorp-
ion.  It  inhibits  the  bacterial  synthesis  of  RNA  by  binding  to
he  -subunit  of  the  bacterial  DNA-dependent  polymerase
NA.7 Its  absorption  is  lower  than  0.4%,  making  it  an  antibi-
tic  that  acts  almost  completely  in  the  gut  lumen,  and
ost  of  it  is  secreted  in  the  feces,  unchanged.  In  addition,
t  has  broad-spectrum  activity  against  Gram-positive  and
ram-negative,  aerobic  and  anaerobic  enteropathogens,
nd  the  probability  of  bacterial  resistance  is  low.7--9
It  has  been  demonstrated  in  the  last  few  years  that  rifax-
min  at  doses  of  400  mg  t.i.d.  for  10  days  or  550  mg  t.i.d.
or  14  days  is  superior  to  placebo  in  the  adequate  response
f  overall  symptoms  and  bloating  in  patients  with  non-
onstipation  irritable  bowel  syndrome  (non-C  IBS)  (Level  IB
vidence,  Grade  A  recommendation).10 Even  though  the  role
f  rifaximin  in  the  microbiota  is  not  clear,  it  has  recently
een  described  to  reduce  Clostridium  concentrations  and
romote  the  growth  of  others,  such  as  Faecalibacterium
rausnitzii.11 In  a  pilot  study  of  15  patients  with  non-C  IBS,
he  administration  of  550  mg  of  rifaximin  t.i.d.  for  14  days
educed  the  Firmicutes/Bacteroidetes  ratio  and  contributed
o  intestinal  biodiversity.11 With  respect  to  the  effects  of
ifaximin  on  the  microbiota,  there  are  many  still  unresolved
uestions  as  to  the  interaction  with  factors  related  to  the
ost  and  the  synergism  with  probiotics  that  most  certainly
ill  be  answered  in  the  not-too-distant  future.
Finally,  it  is  worth  mentioning  that  antimicrobial  resis-
ance  is  also  related  to  factors  not  directly  within  the  realm
f  medical  knowledge,  but  just  as  real,  such  as  antibiotic
se  in  agriculture  and  livestock  production,  quality  in  the
anufacturing  of  medications,  and  environmental  instabil-
ty.  For  all  these  reasons,  I  invite  you  to  read  the  article  by
ovoa-Farías  et  al.  and  reﬂect  upon  their  results.
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